PE-22-28 Peptide

PE-22-28 is a synthetic 7-amino acid peptide analog of Spadin, a natural neuropeptide that inhibits the TREK-1 potassium channel. TREK-1 blockade increases serotonergic neurotransmission, producing rapid antidepressant-like effects in preclinical models within 4 days, compared to 2-3 weeks for classical SSRIs.

PE-22-28 is a synthetic heptapeptide analog of spadin, a natural endogenous peptide derived from the propeptide of sortilin (PE 12-28). Its primary molecular target is the TREK-1 potassium channel (KCNK2), a two-pore-domain background potassium channel highly expressed in regions of the brain implicated in mood regulation, including the prefrontal cortex, hippocampus, and dorsal raphe nucleus.

TREK-1 Channel Blockade

PE-22-28 functions as a selective TREK-1 antagonist. TREK-1 channels normally hyperpolarize neurons by allowing potassium efflux, which dampens neuronal excitability. By blocking TREK-1, PE-22-28 depolarizes serotonergic neurons in the dorsal raphe nucleus, increasing their firing rate and enhancing serotonin (5-HT) release in projection areas such as the hippocampus and prefrontal cortex. This is mechanistically analogous to the disinhibition that classical SSRIs achieve only after weeks of receptor desensitization, which may explain the rapid onset of antidepressant-like effects observed in preclinical models.

Hippocampal Neurogenesis and Synaptic Plasticity

Preclinical studies have demonstrated that TREK-1 blockade by spadin and its analogs increases expression of synaptic markers including PSD-95 and synapsin, and elevates BDNF (brain-derived neurotrophic factor) signaling in the hippocampus. PE-22-28 has been associated with increased hippocampal neurogenesis in rodent models within just 4 days of administration — markedly faster than the 3-4 weeks required for fluoxetine to produce comparable neurogenic effects.

Selectivity Profile

A critical advantage of PE-22-28 over non-selective potassium channel blockers is its high selectivity for TREK-1 over related channels including TREK-2, TRAAK, TASK, and hERG. This selectivity profile is believed to underlie the absence of cardiac arrhythmogenic effects observed with non-specific K2P blockers, and PE-22-28 does not appear to interfere with serotonin reuptake, monoamine oxidase activity, or 5-HT receptor binding directly — distinguishing its mechanism from SSRIs, MAOIs, and tricyclic antidepressants.

Downstream Signaling

The depolarization of serotonergic neurons leads to enhanced firing-dependent serotonin release. Secondary effects include modulation of the mTOR pathway and increased expression of glutamate receptor subunits, which may contribute to the synaptogenic effects observed in preclinical models. Unlike ketamine, which acts via NMDA receptor antagonism to produce rapid antidepressant effects, PE-22-28 achieves rapid onset through a peripheral and central potassium channel mechanism without dissociative or psychotomimetic liabilities reported in animal models.

Stability Advantage Over Spadin

While native spadin (a 17-residue peptide) has a plasma half-life of approximately 7 minutes, PE-22-28 was rationally designed as a shorter, modified analog with substantially improved metabolic stability — extending its functional half-life to approximately 7 hours in rodent plasma, making it a more tractable tool compound for chronic dosing studies.

PE-22-28 is a synthetic heptapeptide analog derived from spadin, a naturally occurring peptide cleaved from the propeptide of sortilin (PE region). It was designed as a shortened, optimized sequence retaining selective blocking activity at the TREK-1 (TWIK-related K+ channel 1) two-pore-domain potassium channel while improving metabolic stability and in vivo half-life compared to the parent spadin molecule. The compound is commonly supplied as a lyophilized white powder for research use only.

The relatively hydrophobic character of PE-22-28 (multiple leucine and valine residues) gives it favorable membrane interaction properties relevant to its action on transmembrane TREK-1 channels. The shortened 7-residue length, compared to the 17-residue parent spadin, contributes to improved proteolytic stability in plasma and prolonged duration of central activity reported in preclinical studies. Researchers should note that the peptide lacks disulfide bridges or cyclization, so reconstituted solutions are not vulnerable to disulfide scrambling but remain susceptible to general peptidase degradation if not kept cold.

PE-22-28 is supplied as a lyophilized powder and must be reconstituted prior to use in research applications. Proper handling preserves peptide integrity and ensures reproducible results in TREK-1 channel modulation and behavioral neuroscience studies.

Reconstitution Protocol

1. Allow the vial to equilibrate to room temperature for 20-30 minutes after removal from -20°C storage. This prevents condensation from forming on the lyophilized cake when the seal is broken.
2. Centrifuge briefly (if a benchtop microcentrifuge is available) to ensure all powder is settled at the bottom of the vial.
3. Select the diluent. Bacteriostatic water (0.9% benzyl alcohol) or sterile water for injection are standard choices. For improved solubility, a small volume of dilute acetic acid (0.1%) may be used as an initial wetting agent before bringing to final volume.
4. Calculate target concentration. A typical working stock is 1 mg/mL: add 5 mL of diluent to a 5 mg vial, or 1 mL to a 1 mg vial.
5. Inject the diluent slowly down the side wall of the vial, not directly onto the peptide cake, to minimize foaming and shear stress.
6. Gently swirl or roll the vial until fully dissolved. Do not shake or vortex vigorously, as this can denature the peptide and generate foam that traps active material.
7. Inspect the solution for clarity. A clear, colorless solution indicates successful reconstitution. Any visible particulates suggest incomplete dissolution or contamination.
8. Aliquot the reconstituted peptide into single-use volumes in low-binding polypropylene tubes to avoid repeated freeze-thaw cycles.

Compound-Specific Handling Notes

PE-22-28 contains no cysteine residues, so oxidative dimerization is not a concern. However, the peptide does contain leucine and proline residues that contribute to its hydrophobic character; researchers may observe slower initial dissolution than with more hydrophilic peptides. Warming the diluent to room temperature (not above 25°C) before addition can aid solubilization. The peptide is sensitive to proteolytic enzymes, so all glassware and pipettes should be clean and protease-free. Avoid contact with metal surfaces that may catalyze degradation. When preparing dosing solutions for in vivo rodent studies, intranasal administration has been used in published protocols at typical concentrations of 1-100 μg/kg; the route bypasses first-pass metabolism and supports rapid CNS delivery characteristic of this compound class. Always wear appropriate PPE (gloves, lab coat, eye protection) when handling peptide powders to prevent inhalation or skin contact.

Proper storage of PE-22-28 is essential for maintaining peptide integrity, TREK-1 blocking activity, and experimental reproducibility. As a lyophilized heptapeptide without disulfide bonds, PE-22-28 is more stable than many larger peptides, but degradation can still occur through hydrolysis, peptidase contamination, or repeated temperature cycling.

Lyophilized Powder Storage

• Long-term storage: Store at -20°C or below in a sealed, desiccated container. Under these conditions, the peptide remains stable for at least 24 months from the date of synthesis.
• Short-term storage: Refrigeration at 2-8°C is acceptable for up to 30 days if the vial remains sealed and protected from humidity.
• Transit: Brief exposure to ambient temperatures (up to 1-2 weeks) during shipping does not significantly compromise the lyophilized powder, owing to its solid state and low water activity.
• Light protection: Although PE-22-28 does not contain highly photolabile residues (no tryptophan), storing the vial in opaque packaging or amber containers is recommended as good general practice.

Reconstituted Solution Storage

• 2-8°C (refrigerated): Reconstituted PE-22-28 in bacteriostatic water is generally stable for 2-4 weeks. Solutions in plain sterile water without preservative should be used within 7-10 days.
• -20°C (frozen aliquots): Single-use frozen aliquots can extend stability to 3-6 months. Freeze-thaw cycles should be avoided; each cycle introduces hydrolytic risk.
• Room temperature: Not recommended for periods exceeding a few hours during active experiments.

Stability Considerations

PE-22-28 lacks methionine and cysteine, so oxidation-related degradation pathways are minimal. The principal degradation routes are aqueous hydrolysis of the peptide bonds (particularly at proline) and proteolytic cleavage if endogenous peptidases are introduced through contaminated diluents or glassware. The shortened sequence relative to spadin contributes to improved in vivo half-life, but in solution at non-refrigerated temperatures, hydrolysis can still occur. Researchers conducting longitudinal in vivo studies should prepare fresh dosing solutions weekly from frozen stock aliquots to ensure consistent dosing. Always label aliquots with reconstitution date and protein concentration, and visually inspect solutions for precipitate or discoloration before use. Discard any solution showing turbidity or color change.